The World’s First T1D-Focused Scaled Venture Fund

Supporting promising companies through investment and expertise to de-risk programs and propel innovation for type 1 diabetes



A Powerful Platform for Collaboration

We exist to catalyze a world without T1D.

At the T1D Fund, our mission is to accelerate treatments, preventions, and cures for type 1 diabetes (T1D) by catalyzing investment in T1D-focused companies. Our primary goal is to support these innovative companies by being a critical thought partner. We leverage our intellectual capital and expert network to offer comprehensive support to our portfolio companies, steering them through regulatory, clinical, and commercial milestones with a combination of scientific expertise, deep industry experience, as well as the network and resources of Breakthrough T1D and The Leona M. and Harry B. Helmsley Charitable Trust.

0

0

0

0

0

The T1D Fund & Breakthrough T1D (Formerly JDRF)

The T1D Fund’s unique network enables a transformative approach to investing in type 1 diabetes

The T1D Fund is a wholly owned, not-for-profit independently run subsidiary of Breakthrough T1D, the leading global organization focused on finding a cure for T1D and supporting those affected by it. Through investment from T1D Fund, our portfolio companies gain access to Breakthrough T1D’s extensive network of research, clinical, and medical expertise, helping to advance and expedite the development of their clinical pipelines.

Together, we are united in our commitment to supporting innovation to accelerate development toward cures.

About The T1D Fund

Launched in 2016, the T1D Fund is the first scaled venture fund established to catalyze the development of T1D cure-oriented therapies through equity investments. The Fund co-invests with venture capital and biopharma in support of early-stage companies pursuing disease-modifying therapies and potential cures for T1D. A core element of our mission is to rapidly advance promising therapies through development and ultimately regulatory approval. The Fund works in close partnership with Breakthrough T1D (formerly JDRF) and The Leona M. and Harry B. Helmsley Charitable Trust—two of the leading global organizations committed to supporting the T1D community and to advancing T1D research and innovation. Led by a deeply experienced team of healthcare and investing professionals, the Fund leverages its vast research, clinical, regulatory, and medical affairs network on behalf of its portfolio companies. Capitalized through philanthropic dollars, the Fund makes investments in biotech companies and recycles returns into new investments, thereby extending the impact of its donors’ contributions.

Contact Us

For more information email us at info@t1dfund.org

© Copyright 2025. All Rights Reserved